

National Institute of Neurological Disorders and Stroke

Translational Research, NINDS Programs

The 18th Annual Non-Dilutive Funding Summit


Charles L Cywin, PhD Director, Small Molecule Neurotherapeutic Development

January 11, 2023







NINDS Offers Programs Across the Translational and Clinical Spectrum



NINDS Offers Programs Across the Translational and Clinical Spectrum



NINDS Offers Programs Across the Translational and Clinical Spectrum



NINDS IGNITE Program

IGNITE Team:

Dr. Becky Roof rebecca.roof@nih.gov Ms. Shruthi Thomas *shruthi.thomas@nih.gov*

Dr. Shardell Spriggs shardell.spriggs@nih.gov Ms. Ashley Givens ashley.givens2@nih.gov

GNITE

Innovation Grants to Nurture Initial Translational Efforts



National Institute of Neurological Disorders and Stroke



IGNITE Goal: Prepare Applicants for Later-Stage Programs

IGNITE is meant to serve a feeder program to later-stage therapy development programs such as the Blueprint Neurotherapeutics Network for Small Molecules or for Biologics







IGNITE Funding Opportunites

PAR-21-124: Assay Development and Therapeutic Agent Identification

PAR-21-123: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery

PAR-21-122: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies


Budget: ≤\$499,000/Year; ≤\$750,000 for Project


Upcoming Application Due Dates: Feb 21, 2023; June 20, 2023

See <u>NOT-OD-15-039</u> for info on late submissions













Milestoned Mechanisms Allow for Dependent Aims

R61 Phase 1: Demonstrate Feasibility and Prepare



Go/No-Go Milestones

R33 Phase 2: The Key Experiment

Extremely Clear, Quantitative and Definitive Milestones are *Essential*

Transition to Phase 2 via Administrative Review



National Institute of Neurological Disorders and Stroke



General Tips for IGNITE

- Contact us in advance
- Have quantitative go/no-go milestones*- see examples <u>here</u>
- Clearly demarcate R61 v R33 activities and timeline*
- Pay attention to non-responsive activities*
- Include a rigorous study design and supporting data (see <u>NOT-NS-11-023</u>)
- Have a multidisciplinary team; note the multidisciplinary review
- Strive to increase the diversity of your team (see <u>NOT-OD-20-031</u>)
- Discuss intellectual property (for therapeutics)
- Have a therapy development plan
- Small Businesses are encouraged to consider the SBIR/STTR program. Contact: Emily Caporello (<u>emily.caporello@nih.gov</u>)
- For a full IGNITE Q&A webinar, see here



* Non-responsive applications will be withdrawn



BPN Program



BPN Staff

Program Director Charles Cywin, PhD

Health Program Specialist Carolyn Bondar, PhD

Operations Coordinator Rakonda Medley, BS

Scientific Project Managers

Pascal Laeng, PhD Enrique Michelotti, PhD Oreisa O'Neil-Mathurin, MPH (EOC) Mary Ann Pelleymounter, PhD Shamsi Raeissi, PhD Ranga Rangarajan, PhD Rebecca Roof, PhD Carol Taylor-Burds, PhD







BPN Program Vision

"Combine Strengths of NIH and Industry Expertise for Small Molecule Neuroscience Drug Discovery"

NIH investigator-initiated ideas

- Solid scientific premise
- Expert disease biology
 - Assays and models

Industry expertise

- Consultants with extensive pharma experience across all R&D spectrum
- Pre-established industry-standard contract services available via BPN

End Goals

- Maintain IP
- Decreased risk as projects advance
- Advance projects to clinic and hand-off





BPN Success Stories

- 38 Projects funded to date covering 8 ICs
- Seven BPN compounds have INDs and first in human trials complete
 - Two projects are now in Phase III (Fragile X/AD (Tetra) & Stargardt's/AMD (Belite))
 - Three projects are in Phase II (MDD (BlackThorn) & Hearing Loss (Oricula), Pain (Eicosis))
 - Two projects completing Phase I (SUD (Eolas) & epilepsy (Knopp-(now BioHaven))
- Two more INDs and Phase I studies expected to start in 2023 (SUD and pain)
- Three additional INDs and trials supported ad hoc
 - NCCIH: Assisted in IND enabling activities for (now in Phase III (Nicotine addiction) (Achieve))
- Ten projects have announced additional industry funding since utilizing the BPN
 - Valued at close to 2-billion dollars in potential investments
















Advance Projects for Hand-Off

"Grand Challenge to Provide Grant Funding and Resources to Facilitate Small Molecule Drug Discovery and Development to Treat Nervous System Disorders"








Blueprint Neurotherapeutics Network (BPN) Customized Combo of Infrastructure, Expertise, and Funds










National Institute of

and Stroke

Participating Institutes: NCCIH, NEI, NIA, NIAAA, NICHD, NIDA, NIDCR, NIMH, and NINDS eurological Disorders

BPN – Projects Can Enter at Any Preclinical Stage





Next Anticipated Application Date: February 9, 2023


15

Neurotherapeutics Network for Biologics

BPN-Biologics

A Customized Combination of Infrastructure, Expertise, and Funding

- Cooperative agreement and SBIR Fast-Track award programs support biologics discovery and development
- > Access to consultants and contracts that provide discovery, preclinical development, and clinical trial support



Projects can enter at either the:

- Discovery stage: for lead characterization and optimization to improve the potency and/or suitability for clinical testing
- Development stage: to advance a development candidate through IND-enabling toxicology studies and Phase I clinical testing



National Institute of Neurological Disorders and Stroke

NIH Blueprint

https://neuroscienceblueprint.nih.gov/neurotherapeutics/bpn-biologics



NCCIH NEI NIA NIAAA NIBIB NICHD NIDA NIDCR NIMH NINDS OBSSR


HEAL Pain Therapeutics Development Program (PTDP)

Hit/Lead Optimization Lead Selection/Lead Characterization IND Enabling Studies

Phase I Clinical Trial

Virtual Pharma Approach Featuring Industry-Experienced Consultants and NIH Contract Resources

- Supports biologic and small molecule therapeutic development
- NIH Consultants are assigned and tailored to each project based on needed expertise
- NIH Contract resources are tailored to stage of each project
- Awardee can choose which NIH contracts to use or opt to budget their own contracts in grant proposal
- PI team's Intellectual Property Retained by PI's Institution





Grant: "Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain-UG3/UH3", RFA-NS-21-010

Features of the PTDP Grant: RFA-NS-21-010


Goal: Accelerate development of novel, non-opioid, non-addictive analgesics

Grant Features:	End Goals & Milestones
 Phased, milestone driven cooperative agreement grant Supports Hit to Lead activities 	 ✓ Identify and fully characterize a lead candidate ✓ Identify target engagement biomarker if possible ✓ Seek partnerships
 Supports lead optimization, selection and characterization 	 ✓ Complete IND enabling studies ✓ File IND
 Supports biomarker optimization and PK/PD development 	 ✓ Complete Phase I trial(s) ✓ Ready for Phase II clinical trial
 Supports IND-enabling studies and Phase I trials 	

Remaining receipt Dates: February 14, 2023, June 15, 2023 and October 17, 2023 Contact : Mary Ann Pelleymounter (mary.pelleymounter@nih.gov)

A Snapshot of HEAL Pain Therapeutics Development Program Funded Research

Pain Condition and Stage



PTDP has a diverse mix of therapeutic targets and pain indications with roughly even proportions of biologic and small molecule modalities.

Types of Mechanisms

- Funding Opportunity Announcements (FOAs)
 - Read the each FOA carefully
 - PA vs PAR vs RFA: Each one can have different requirements, review criteria, eligibility etc.
 - Is it a Cooperative Agreement (U-grant vs. R-grant)?
 - Is it milestone based?
 - Is it an SBIR mechanism?
 - Follow the instructions in the FOA
 - Failure to do so may result in your application being withdrawn from consideration prior to review.





Plan with the End in Mind

Target population

- Pediatric vs. adult patients?
- Early vs. advanced disease?

• Dosing regimen

- Chronic or acute treatment?
- Frequency?

• Route of administration

- Oral? IV? Eye drops? Transdermal? etc.

• Desired outcome

– Comparison to standard of care?

Engage clinicians in developing a Target Product Profile





Hit Compound ≠ Clinical Candidate

- Is there a sufficient therapeutic window between activity at desired and undesired targets?
 - hERG inhibition?
 - Other off-target effects?
 - Inhibitor of common CYPs?



• Is PK/PD consistent with the dosing strategy in the Target Product Profile?




National Institute of Neurological Disorders and Stroke Profile your compound early on



Incorporate IP into Your Strategy

- Consider future licensing strategy
- Don't develop someone else's compound
- Avoid encumbering your own future work



Contact your Tech Transfer/Business Development official early on





Some Things To Do

- Preliminary and supporting data
 - Explicitly discuss the quality of the data presented in prior publications in a detailed manner. Were they done in a rigorous manner, utilizing randomization, blinding, inclusion/exclusion criteria and the appropriate power analysis
- Rigor
 - Detail the controls being used for each type of experiment and appropriately highlight potential confounds like surgery exposure, genotype, culture-to-culture variability, and human placebo effects.
 - Include details within the experimental design about the reduction of potential bias, including blinding, randomization, and inclusion/exclusion criteria.
 - Describe the source of the data on which the sample size estimation (power analysis) is based **and** details about the analysis itself.





Questions?



Rebecca Roof, PhD IGNITE rebecca.roof@nih.gov

Charles Cywin, PhD Blueprint Neurotherapeutics (BPN) <u>charles.cywin@nih.gov</u>

Mary Ann Pelleymounter, Ph.D. HEAL Pain Therapeutic Development Program (PTDP) mary.pelleymounter@nih.gov

Carol Taylor-Burds, PhD Biomarkers carol.taylor-burds@nih.gov

https://www.ninds.nih.gov/current-research/research-funded-ninds/translational-research



National Institute of Neurological Disorders and Stroke

